Rivaroxaban for Symptomatic Isolated Distal Deep Vein Thrombosis

Phase 3, randomised, single-blind trial of rivaroxaban in isolated distal deep vein thrombosis (IDDVT) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Radiographically confirmed recurrent venous thromboembolism at 6 months and Major or clinically relevant non-major bleeding events at 3 months. Status: unknown.